Vizia Diagnostics to Facilitate Ordering Of the TissueCypher® Test

Alpharetta, GA—VIZIA Diagnostics, an established gastrointestinal pathology lab, will now facilitate orders for TissueCypher, an AI-driven precision medicine test designed to provide personalized cancer risk predictions for patients with Barrett’s esophagus. The test helps identify patients most likely to progress to esophageal cancer, an area in which traditional assessments often fall short. 

VIZIA Diagnostics is excited to bring the advanced capabilities of TissueCypher testing to its partnering gastroenterologists, offering a powerful tool for the risk stratification of Barrett’s esophagus patients. “At VIZIA, our ability to facilitate orders for the TissueCypher test expands our service offerings, solidifying our role as a leader in GI diagnostic innovation,” said Ed Cochrane, Commercial Director of VIZIA Diagnostics. “The TissueCypher test provides clinicians with powerful, actionable data, which can ultimately benefit patients through early, personalized intervention opportunities and better-informed care decisions.”

By analyzing cellular, molecular, and morphologic information from a patient’s tissue biopsy, TissueCypher delivers a 5-year probability of progression to high-grade dysplasia or esophageal cancer. This risk assessment integrates with clinical guidelines, enabling healthcare providers to make well-informed decisions for Barrett’s esophagus patients and helping reduce the uncertainty associated with traditional dysplasia-based risk grading.

“The fact that VIZIA makes it easy to have the TissueCypher test run for my patients is great,” says Dr. Sunil Lal at Doctors Specialists Gastroenterology in Augusta, GA. “VIZIA provides the initial analysis for my patients’ esophageal biopsies collected during standard endoscopy. Depending on the initial analysis, VIZIA then sends the biopsy samples to the TissueCypher lab to run the test. The specific test results that I receive help inform the appropriate interval of surveillance for my Barrett’s patients.”

TissueCypher Key Features:

• Risk Classification: Categorizes patients into low, intermediate, or high-risk groups for cancer progression.
• Risk Score: Provides a personalized score on a 0-10 scale, where lower scores signify reduced cancer risk.
• 5-Year Progression Risk: Supplies an individualized percentage of cancer risk over a 5-year period, supporting long-term clinical planning.

About VIZIA Diagnostics

VIZIA Diagnostics is a recognized leader in gastrointestinal pathology, dedicated to enhancing diagnostic services through innovative processes and exceptional patient care. As a trusted healthcare partner, VIZIA utilizes advanced technology and the expertise of its skilled team to provide precise, timely, and dependable results, setting new industry standards for quality in GI diagnostics and improving patient outcomes. For more information, please visit www.viziadx.com.

About TissueCypher® Barrett’s Esophagus test

The TissueCypher Barrett’s Esophagus test is Castle Biosciences’ precision medicine test designed to predict future development of high-grade dysplasia (HGD) and/or esophageal cancer in patients with Barrett’s esophagus (BE). The TissueCypher Barrett’s Esophagus test is indicated for use in patients with endoscopic biopsy-confirmed BE that is graded non-dysplastic (NDBE), indefinite for dysplasia (IND) or low-grade dysplasia (LGD); its clinical performance has been supported by 14 peer-reviewed publications of BE progressor patients with leading clinical centers around the world. The test received Advanced Diagnostic Laboratory Test (ADLT) status from the Centers for Medicare & Medicaid Services (CMS) in March 2022. Learn more at www.CastleBiosciences.com.

Helpful Resources

• Understanding Barrett’s Esophagus and Cancer Risk
• Diagnosis and screening for Barrett’s esophagus
• Barrett’s esophagus is the only known precursor to esophageal adenocarcinoma
• Barrett’s Esophagus Treatment and Management
• Personalized progression risk assessment with TissueCypher

Barrett’s esophagus terms and definitions